Maynard, MA—
October 30, 2018 — EmpiraMed, Inc., a leader in the field of patient engagement software, today announced that our Chief Medical Officer, Neil Minkoff MD, has authored a paper to be published in the November 2018
Managed Care journal.
The title of the paper, which is part of the
Managed Care Viewpoint series, is entitled, “Patient Reported Outcomes: You’ll Get a Lot More Responses If You Make it Fun To Do.”
Dr. Minkoff explained, “I’ve been working on patient engagement in managed care since the 1990s; I’ve learned that Real World Patient Experience is the only way to effectively implement population health.”
EmpiraMed has developed novel technology to maximize patient engagement through the use of intuitive and compelling user experience, mobile device independence, gamification, and a multi-faceted Rewards Program. This article shows that for non-interventional observational clinical studies, EmpiraMed has achieved an unsurpassed 95% annual retention rate, a monthly survey completion rate of over 75%, and electronic diary utilization of over 3 times per week.
Dr Minkoff added, “These patient engagement statistics surpass current standards threefold, and we’re excited to share our learnings with the whole industry through this article in
Managed Care.”
“We are thrilled to support the efforts of managed care companies to engage patients more effectively than ever before. Generating Real World Evidence through patient experience is especially important in rare diseases, drug pricing justification, market access, and FDA-mandated Phase IV studies.” said Greg Erman, President & CEO of EmpiraMed.
As explained in this article, EmpiraMed’s innovative technology allows for the flexibility to capture different types of patient data in ways that are fun and enticing, leading to higher levels of PRO data capture than previously possible.
According to Dr. Minkoff, “We can integrate patient self-reported information with other data, including claims and EHR data, to truly understand the complete patient experience.”
The article will be in the print November 2018 issue of Managed Care and is currently available at:
https://www.managedcaremag.com/archives/2018/11/patient-reported-outcomes-you-ll-get-lot-more-response-if-you-make-it-fun-do
About EmpiraMed
EmpiraMed has created a novel
decentralized (or virtual) trial and registry
patient-engagement software platform to generate
Real World Evidence for the Life Science Industry. We have developed three products. The EmpiraMed™ PRO Portal™ Software Platform offers unsurpassed user “stickiness” to directly capture real world patient experience. Combining our fully automated study execution rules-engine, novel patient recruitment methods, and true mobile device independence, EmpiraMed delivers the most robust decentralized clinical study solution available. To that end, many of our prospective RWD studies are 100% site-less, from patient recruitment to execution, which few vendors can claim. Non-interventional studies typically suffer from poor patient participation, so our portal includes the ground-breaking Rewards Program which has improved patient engagement to more than 3X current industry standards. Consequently, our customers have seen dramatic increases in patient participation, compliance, wearable device utilization, and overall study success. In addition, our customers can now use this next-generation technology to file new indications for regulatory approval under the EmpiraMed™ DESTINI™ program, which is designed to reduce costs, expand patient access, and shorten time to market. To support Post Market Required Phase IV Studies, EmpiraMed has developed the PMR Portal™ patient medical record system to capture clinic routine care data while substantially reducing clinic burden and contracting. The PMR Portal directly addresses a common problem of poor clinic participation in regulatory agency mandated studies. We also offer an EDC and comprehensive forms management system for clinic study-specific data called the MED Portal™ platform. These three products have been used by R&D, Medical Affairs, HEOR, and Market Access to measure comparative effectiveness, demonstrate the value of treatments to prescribers, reduce reimbursement barriers, defend pricing, support REMS, implement longitudinal rare disease registries, develop Outcomes Based Contracting Programs that go beyond claims data, and offer Quality Improvement Intervention Projects to improve medication adherence. EmpiraMed’s software and services support all industry compliance requirements including HIPAA, GDPR, 21 CFR Part 11, and GCP. Studies can be internationalized using our automated, rules-based, localization system. Global leaders have used EmpiraMed’s technology in a wide variety of therapeutic areas since 2011, and our customers have included prominent biopharmaceutical manufacturers such as
Merck Sharp & Dohme,
Biogen,
Janssen,
Sanofi Genzyme,
United Therapeutics,
Teva, and
Takeda. EmpiraMed also has contracts with leading Patient Advocacy Groups and Specialty Pharmacies to offer the Life Science Industry a unique and broad decentralized study solution.